Physician profile
Patrick B Gipe
NPI 1598761702
$1,586.60
in general payments reported to CMS, 2019-2025
27 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $120 · 2022: $38.00 · 2023: $163 · 2024: $90.00 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.09 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $203.61 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $147.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $131.15 | 2019-2023 | |
| Amarin Pharma, INC. | $119.78 | 2019 | |
| Amgen INC. | $112.26 | 2019-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.48 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $97.51 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $95.73 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.00 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $64.01 | 2019 | |
| Exact Sciences Corporation | $59.45 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $52.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $52.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.78 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $39.19 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.17 | 2023 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $21.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.71 | 2019 | |
| Abbott Laboratories | $18.25 | 2024 | Freestyle Libre 3 |
| Allergan, INC. | $15.18 | 2020 | |
| Inspire Medical Systems, INC. | $13.81 | 2024 | Inspire |
| Genentech USA, INC. | $12.79 | 2020 | |
| Mylan Specialty L.P. | $12.50 | 2019 | |
| Abbvie INC. | $11.22 | 2019 | |
| Sanofi Pasteur INC. | $11.22 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.89 | 2019 | |
| Endogastric Solutions, INC | $10.24 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.